ClinicalTrials.gg
WithdrawnNCT04133480EPI-COGUpdated Sep 1, 2022

Investigation of Cognitive Outcomes With Cannabidiol Oral Solution

A Phase 4 interventional study of GWP42003-P in Lennox-Gastaut Syndrome, sponsored by Jazz Pharmaceuticals. Withdrawn. Open to participants aged 3 Years to 10 Years. Per ClinicalTrials.gov, last updated 2022-09-01.

Sponsored by Jazz Pharmaceuticals · Phase 4, Interventional, and Treatment

Why this study was withdrawn
The decision to withdraw the study was based on pandemic-related concerns of conducting a Phase IV study requiring multiple clinic visits when medication is commercially available. The study was withdrawn before any participants were recruited.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
3 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing cannabidiol in Lennox Gastaut Syndrome — 2 open to participants now, 3 under way, none of them phase 3. Cannabidiol · Lennox Gastaut Syndrome.

Enrollment
12th of 13
0 · median 40
Started
2020
with 1 other
Phase 4
4 of 13
2 open now
Registered
9th of 13
by date
Lead sponsor
6 of 13
Jazz Pharmaceuticals

Among the 13 studies testing cannabidiol in Lennox Gastaut Syndrome, this one is the 12th largest by enrollment, is one of 2 that started in 2020, is one of 4 in phase 4, and was the 9th registered.

Lennox Gastaut Syndrome

68 studies on the registry are indexed under Lennox Gastaut Syndrome; 13 are open to participants now.

Browse Lennox Gastaut Syndrome studies →

Open to participants now

2 of the 13 studies testing cannabidiol in Lennox Gastaut Syndrome are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 4 Lennox Gastaut Syndrome studies recruiting now, none set no upper age limit and 4 stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 3 Years to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing cannabidiol in Lennox Gastaut Syndrome, or all of them as a file.
02

Study summary

This study is being conducted to evaluate the effects of GWP42003-P on cognition in pediatric participants, aged 3 to 10 years, with Lennox-Gastaut Syndrome (LGS).

Read the detailed description

This trial is a 30-week (4-week baseline period; 26-week treatment period) open-label exploratory investigation of the effects of GWP42003-P on cognitive abilities in participants with LGS who reside in the United States.

03

Conditions studied

  • Lennox-Gastaut Syndrome

Keywords

  • GWP42003-P
  • EPIDIOLEX®
  • cannabidiol
  • CBD
  • cognition
04

Who can participate

Ages eligible
3 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participant is male or female aged 3-10 years.
  • Participants' parent(s)/legal representative is willing and able to give for participation in the trial; where the participant possesses adequate understanding, informed assent should also be taken.
  • Participant and their caregiver are willing and able (in the investigator's opinion) to comply with all trial requirements.
  • Participant must have a clinical diagnosis of Lennox-Gastaut Syndrome (LGS), with onset within the last 5 years. This includes certification from the investigator of prior electroencephalogram (EEG) documenting slow spike wave (\< 3 Hertz [Hz]) during the participant's history and evidence of more than 1 type of generalized seizure, including drop seizures (atonic, tonic, or tonic-clonic), for at least 6 months.
  • Investigator can confirm that the addition of GWP42003-P to the participant's existing antiepileptic drug (AED) regimen is warranted.
  • Participant must have at least 1 drop seizure each week during the first 28 days of the baseline period.
  • A minimum level of general intellectual functioning as assessed at screening with the Peabody Picture Vocabulary Test
  • Participant's parent(s)/legal representative is willing to allow the responsible authorities to be notified of participation in the trial, if mandated by local law.
  • Participant's parent(s)/legal representative is willing to allow his or her primary care practitioner (if they have one) and consultant (if they have one) to be notified of participation in the trial, if the primary care practitioner/consultant is different to the investigator.

Key Exclusion Criteria:

  • Participant has unstable medical conditions other than epilepsy.
  • Participant experiences > 300 total seizures within the first 28 days of the baseline period.
  • Participant has any prior exposure to GWP42003-P.
  • Participant has initiated felbamate within the last 12 months.
  • Participant has initiated mammalian target of rapamycin (mTOR) inhibitors for epilepsy within the last 4 weeks.
  • Participant is currently using or has in the past used recreational or medicinal cannabis or synthetic cannabinoid-based medications (including Sativex®) within the 3 months prior to trial entry.
  • Participant has had clinically relevant symptoms or a clinically significant illness, other than epilepsy, in the 4 weeks prior to screening or Visit 2.
  • Participant has laboratory values at screening or Visit 2 that are clinically significantly abnormal in the investigator's opinion.
  • Participant tests positive for Δ9-tetrahydrocannabinol (THC) or cannabidiol (CBD) at screening.
  • Participant has any known or suspected to cannabinoids or any of the of GWP42003-P.
  • Participant has significantly impaired hepatic function at the screening visit, defined as any of the following:

    • Serum (ALT) or aspartate aminotransferase (AST) > 5 × (ULN);
    • Serum ALT or AST > 3 × ULN and (total [TBL] > 2 × ULN or [INR] > 1.5);
    • Serum ALT or AST > 3 × ULN with the presence of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (> 5%).
  • Participant has received an medical product within the 3 months prior to the screening visit.
  • Participant has any other significant disease or disorder, which, in the opinion of the investigator, may either put the participant at risk because of participation in the trial, may influence the result of the trial, or may affect the participant's ability to take part in the trial.
  • Any abnormalities identified following a physical examination of the participant that, in the opinion of the investigator, would jeopardize the safety of the participant if he/she took part in the trial
  • Participant has been previously enrolled into this trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    GWP42003-P

    For the first 7 days of the treatment period, participants are to take GWP42003-P at a dose of 5 milligrams per kilogram per day (mg/kg/day), administered as 2 equally divided doses (i.e., 2.5 mg/kg in the morning and 2.5 mg/kg in the evening). On Day 8, participants are to increase the dose to 10 mg/kg/day, administered as 2 equally divided doses (i.e., 5 mg/kg in the morning and 5 mg/kg in the evening). The 10 mg/kg/day dose should be maintained for the remainder of the treatment period; however, per labeling, investigators may increase the dose to a maximum of 20 mg/kg/day if clinically warranted by titrating an additional 5 mg/kg/day each week until reaching the maximum dose. GWP42003-P will be taken b.i.d. (morning and evening).

    Drug: GWP42003-P

Interventions

  • oral solution of 100 milligrams per milliliter (mg/mL) cannabidiol (CBD)

    Also known as: Cannabidiol, CBD, Epidiolex

06

What researchers measure

Primary outcomes

  1. Change from Baseline to end of treatment (Day 181 [Visit 5]) in processing speed on the National Institutes of Health Toolbox Cognition Battery (NIHTCB)

    Time frame: Baseline; Day 181

Secondary outcomes

  1. Change from Baseline to Day 91 (Visit 4) in processing speed on the NIHTCB

    Time frame: Baseline; Day 91

  2. Change from Baseline to Day 91 (Visit 4) and Day 181 (end of treatment; Visit 5) in executive function and attention on the NIHTCB

    Time frame: Baseline; Days 91 and 181

  3. Change from Baseline to Day 91 (Visit 4) and Day 181 (end of treatment; Visit 5) in episodic memory on the NIHTCB

    Time frame: Baseline; Days 91 and 181

  4. Change from Baseline to Day 91 (Visit 4) and Day 181 (end of treatment; Visit 5) in language on the NIHTCB

    Time frame: Baseline; Days 91 and 181

  5. Change from Baseline to Day 91 (Visit 4) and Day 181 (end of treatment; Visit 5) in the NIHTCB Childhood Composite Score

    Time frame: Baseline; Days 91 and 181

  6. Change from Baseline to Day 91 (Visit 4) and Day 181 (end of treatment; Visit 5) in the Behavior Rating Inventory of Executive Function, Second Edition (BRIEF-2) or BRIEF, Preschool (BRIEF-P) for participants aged 5 years or younger

    Time frame: Baseline; Days 91 and 181

  7. Change from Baseline to Day 91 (Visit 4) and Day 181 (end of treatment; Visit 5) in weekly seizure frequency

    Time frame: Baseline; Days 91 and 181

  8. Change from Baseline to Day 91 (Visit 4) and Day 181 (end of treatment; Visit 5) in behavior using the Aberrant Behavior Checklist, Second Edition Community Forms (ABC-2-3)

    Time frame: Baseline; Days 91 and 181

  9. Change from Baseline to Day 91 (Visit 4) and Day 181 (end of treatment; Visit 5) in sleep characteristics using the Children's Sleep Habits Questionnaire (CSHQ)

    Time frame: Baseline; Days 91 and 181

  10. Change from Baseline to Day 181 (end of treatment; Visit 5) in quality of life using the Pediatric Quality of Life Inventory (PEDS-QL4)

    Time frame: Baseline; Day 181

  11. Change from Baseline to Day 91 (Visit 4) and Day 181 (end of treatment; Visit 5) in generic health status using the EQ-5D-Y Proxy Version 1

    Time frame: Baseline; Days 91 and 181

  12. Change from Baseline to Day 91 (Visit 4) and Day 181 (end of treatment; Visit 5) in the Caregiver Global Impression of Change (CGIC) score

    Time frame: Baseline; Days 91 and 181

  13. Change from Baseline to Day 91 (Visit 4) and Day 181 (end of treatment; Visit 5) in Patient-Reported Outcomes Measurement Information System (PROMIS®) - Parent Proxy Short Form Anxiety and Depression Subscales

    Time frame: Baseline; Days 91 and 181

  14. Change from Baseline to Day 91 (Visit 4) and Day 181 (end of treatment; Visit 5) in Parenting Stress Index, Fourth Edition (PSI-4)

    Time frame: Baseline; Days 91 and 181

  15. Change from Baseline to Day 181 (end of treatment; Visit 5) in the participant's ability to perform day-to-day tasks

    Time frame: Baseline; Day181

  16. Change from Baseline to Day 91 (Visit 4) and Day 181 (end of treatment; Visit 5) in the Physician Global Impression of Change (PGIC) score

    Time frame: Baseline; Days 91 and 181

  17. Number of participants with the indicated type of adverse event

    Time frame: up to Day 219

  18. Number of participants with clinically significant changes in laboratory parameter values

    Time frame: Baseline; up to Day 191

  19. Number of participants with clinically significant changes in physical examination findings

    Time frame: Baseline; up to Day 191

  20. Number of participants with clinically significant changes in vital sign values

    Time frame: Baseline; up to Day 191

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2020; primary completion for Dec 2021, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2019
First posted
Oct 21, 2019
StartEst.
Oct 2020
Primary completionEst.
Dec 2021
CompletionEst.
Dec 2021
Last update
Sep 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04133480
Responsible party
Sponsor
First posted
Oct 21, 2019
Start date
Oct 2020 (estimated)
Primary completion
Dec 2021 (estimated)
Completion
Dec 2021 (estimated)
Last update
Sep 1, 2022

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion